Delayed hypersensitivity to hepatitis B surface antigen (HBsAg) in patients with disease from the clinical spectrum of hepatitis and in controls was examined by an indirect assay of macrophage migration inhibitory factor. Activity was demonstrated in cases of acute or persistently active hepatitis. Steroids and pregnancy had a suppressive effect. Samples from a patient with transfusion-related HBsAg hepatitis were also assayed.
niotic fluid from eggs inoculated with presumed infectious hepatitis virus. Delayed skin reactions to HBsAg have been demonstrated in guinea pigs [6] . Since a reproducible nonhuman assay for purified HBsAg infectivity is not available at present, skin tests in patients have not been performed. Instead, in vitro correlates of delayed hypersensitivity have been applied, with varying results. Initial experiments with phytohemagglutinin stimulation produced negative results because of apparent hyporesponsiveness of lymphocytes in acute serum hepatitis [7, 8] . More recently, increases in the uptake of thymidine by lymphocytes of patients with a documented history of HBsAg hepatitis have been described [9] . In the present study, delayed hypersensitivity to HBsAg in humans was examined by the indirect macrophage migration inhibitory factor (MIF) assay [10] .
Materials and Methods
The in vitro MIF assay was modified according to the technique of Rocklin et al. [10] . A 50-ml sample of heparinized blood (1,000 V/50 ml) was obtained in a plastic syringe from each of 50 individuals in various clinical categories related to serum hepatitis. The blood was allowed to sediment by gravity for 1 hr at 37 C. Dextran was used in nine cases where there was no significant separation of red blood cells from plasma after 30 min. The leukocyte-rich plasma was harvested, centrifuged at 1,000 g for 5 min, and washed three times in 20 ml of Hanks' balanced salt solution (HBSS). Lymphocytes were adjusted to a concentration of 2.0-2.5 X 10 7 cells/rnl in TC 199 medium (Grand Island Biological, Grand Island, N.Y.), containing 15% heat-inactivated yglobulin-free fetal calf serum, 100 ug of penicillin/ ml, and 50 ug of streptomycin/mI. Cotton filtration was not performed. This suspension was divided into two parts: a control tube and a tube to which 0.025 ml of a purified preparation of HBsAg subtype y was added. When possible, a third tube for subtype d was included. All lymphocyte suspensions were incubated at 37 C in rubberstoppered glass tubes. After 24 hr, supernatants were harvested and stored at -70 C until MIF assay.
The production of MIF was measured with guinea pig peritoneal exudate cells (PEC) as indicator cells. Adult white male English guinea pigs (700-800 g) were inoculated ip with 30 ml of white petroleum oil (Marcol's, Exxon Oil Company, USA). HBSS (100 ml) was injected ip 72 hr later, and the PEC were harvested. Differential cell counts revealed 70%-80% macrophages, 19% -29 % lymphocytes, and 1% polymorphonuclear leukocytes. The cells were washed three times in cold HBSS and adjusted to a concentration of 10% (vol/vol) in HBSS. Capillary tubes were filled to 75% capacity with PEC, and one end was sealed with paraffin wax. The sealed capillary tubes were centrifuged for 1 min at approximately 800 g and cut at the interface of cells and HBSS. Two capillary tubes were placed in each plastic chamber (Mackaness ChambersBerton Plastics, Hackensack, N.1.).
Cover glasses were fixed to the bottom and the top of the chambers with silicone grease. At least two chambers of tubes were tested for all controls and super nates (total of four tubes each). For tests of supernatants 0.1 ml of supernatant was mixed with 0.5 ml of medium (pH 7.4) in each chamber. All chambers were incubated at 37 C for 24 hr. The areas of migration of PEC out of the capillary tubes were measured by projection and planimetry. All supernatants were tested against PEC from at least two guinea pigs on different days. Supernatants to be retested were refrozen at -70 C.
The migration index for each experiment was Antigen purification and HB"Ag subtypes. HBsAg was purified as previously described [6] . The CF titer [11] of antigen was 1: 8, and the protein concentration was 40 ug/rnl. For stimulation of lymphocytes and for the antigen toxicity control in the MIF assay (medium plus HBsAg), 0.025 ml of purified HBsAg/ml of medium was used. When possible, human lymphocyte suspensions were divided into three aliquots (a control and one tube each for challenge with HBsAg subtypes y and d [12] ). The MIF assay was conducted as above with controls for both HBsAg subtypes included.
Patients. The above MIF assay was performed with lymphocytes from 50 people. Serial samples of blood were obtained when possible. The clinical and epidemiological characteristics of each patient are summarized in tables 1 and 2.
All hospital records were reviewed. Liver biopsies were done on 34 patients, either during illness at the time of MIF testing, or at some earlier time. Biopsy specimens were read independently of the MIF tests and classified as indicating classic hepatitis (mild, moderate, or severe) , subacute hepatic necrosis, or postnecrotic cirrhosis, according to criteria previously described [13] .
Results
The detection of MIF by the in vitro assay is shown according to the clinical category of the HBsAg spectrum in figure 1 . Patients with HBsAg positive acute hepatitis and Hls.Ag-positive or -negative persistent hepatitis produced MIF. MIF activity was not detected in patients who were receiving steroids or in pregnant patients with acute HBsAg-positive hepatitis. Patients with a documented history of Hls.Ag-posrtive mild hepatitis (six months to two years previous) but without continuing clinical or laboratory evidence of liver disease did not demonstrate MIF. HBsAg-positive carriers without evidence of liver disease also had no evidence for MIF activity. Patients with acute hepatitis epidemiologically related to ingestion of shellfish and without a history of drug use or exposure to blood products (probably hepatitis A) did not produce MIF. Individuals with antibody to HBsAg detectable by hemagglutination [14] and/or precipitation in agar gel did not make MIF, nor did antibodynegative normal controls. Thirty-three parallel determinations of MIF from the same patients using subtype d purified HBsAg in the in vitro challenge showed entirely parallel results.
The results of a study of the lymphocyte samples of one patient who inadvertently received a unit of HBsAg-positive blood are recorded in figure 2. Samples were obtained on days 8, 38, 84, 98, 154, and 195 after transfusion. Clinical illness with laboratory evidence of liver injury occurred between days 81 and 123. HBsAg was Results from all categories of patients were reproducible; i.e., if MIF was present initially, it could be detected on repeated testing of the same supernatant against PEC from other guinea pigs. In some cases, however, the degree of inhibition in the second test was lower than that in the original test. None of the supernatants originally found not to contain MIF inhibited migration of PEC on second testing. In a few patients marked enhancement of migration of PEC (mi- dent on the presence of clinical illness at the time of the assay. Those patients with acute HBsAgpositive hepatitis and those with persistent hepatitis B (either positive or negative for HBsAg), produced detectable MIF. Corticosteroids and pregnancy suppressed MIF activity. Asymptomatic carriers of HBsAg, individuals with antibody to HBsAg, and normal controls did not make MIF. MIF activity in this system was not found in patients with apparent hepatitis A.
In one individual who was mistakenly given a unit of HBsAg-positive blood, MIF was not detectable on two occasions before the appearance of clinical illness. During and shortly after clinical illness, MIF was present; it was undetectable again 72 days after disappearance of abnormal liver function and clinical signs and symptoms.
Although HBsAg is thought to be related to the virus of hepatitis B, the mechanism of viral replication in vivo and the relation to liver cell antigens is unclear. Histologically, the presence of a mononuclear cell infiltrate in the liver of patients with acute and chronic hepatitis is in accord with a delayed cellular immune response. If HBsAg in the course of its synthesis is located in the cytoplasm of liver cells or is released from cell membranes, a cellular immune response to viral antigens and/or liver cell antigens is plausible.
Early in vitro assays for delayed hypersensitivity in patients with hepatitis suggested that their lymphocytes were hyporesponsive to phytohemagglutinin stimulation [7, 8] . Recently, lymphocyte transformation by serum containing HBsAg has been reported in patients who have recovered from serum hepatitis [9] . Ito et al. [15] noted inhibition of migration of leukocytes in patients with chronic and persistent hepatitis.
Lymphocytes sensitized to liver cell antigens are important in the pathogenesis and transfer of experimental murine liver disease [16] . Similarly, direct assays of leukocyte migration inhibition with liver antigens have been used to monitor rejection of liver homografts [17] , and the transformation of lymphocytes to lymphoblasts after stimulation with hepatic antigens has been noted in chronic active hepatitis and primary biliary cirrhosis [18] .
The lack of detectable MIF activity in the absence of recent clinical disease is unlike the increased uptake of thymidine by lymphocytes of convalescent patients. Although the explanation for this paradox is unclear, it may be related to the insensitivity of the MIF test to purified HBsAg, decreased numbers of sensitized cells at a point beyond clinical disease, or an in vitro manifestation of a liver that is healed. It is also possible that lymphocytes from patients with acute viral disease are nonspecifically stimulated to release lymphokines.
It has been reported that lymphocyte and fibroblast lines release MIF spontaneously [19] [20] [21] . In the present study, it was doubtful that MIF was being spontaneously released, because it could not be detected in control supernates containing no purified HBsAg. Why cells obtained from patients with antigenemia and acute hepatitis showed in vitro stimulation was unclear. However, control cells removed from the patient and washed do not produce MIF, as do those stimulated with HBsAg.
The factor that distinguishes the patient with an acute HBsAg-positive case of hepatitis from the asymptomatic carrier may be one of the above. Although no direct skin tests with purified HBsAg have been done in patients, there are some indications in carriers that possibly immunological tolerance to circulating antigen allows indefinite viral replication. In the present study, two asymptomatic carriers who were given skin tests for anergy with mumps, trichophyton, monilia, and streptokinase-streptodornase antigens had positive reactions to one or more of the antigens. How- ever, it has been reported that persistent carriers are difficult actively to sensitize to dinitrochlorobenzene [2] . If "tolerance" is the pathophysiologic mechanism in the asymptomatic carrier, it must involve a narrow range of antigen (s) and specifically HBsAg. Paradoxically, the patient with Hll.Ag-positive chronic hepatitis, although a carrier, may have broadened his immunological response to include liver cell antigens with or without an immune response to HBsAg.
Subtypes have served as epidemiological markers of outbreaks of HBsAg hepatitis [22, 23] . In densely populated areas both subtypes have been found, and epidemiological tracing is more difficult. The question of cross-immunity between subtypes has been raised with regard to natural infection and possible vaccine production. Precipitating antibody to HBsAg is predominantly to the common a antigen and occasionally to other determinants. Delayed skin reactions to both subtypes have been demonstrated in guinea pigs immunized with either d or y subtypes (authors' unpublished observations). In the present study, cross-reactions between d and y subtypes of HBsAg were demonstrated for patients in vitro. It is unknown whether immunity 10 the heterogeneous subtype of HBsAg in a patient who has recovered from acute hepatitis caused by another subtype is sufficient to protect against clinical reinfection. Presumably the cross-immunity between HBsAg subtypes in vitro is due to their common antigenic determinant, a.
The wisdom of clinical use of steroids in acute hepatitis has been debated for many years [24] . Prior to the discovery of HBsAg, controlled studies showed a rapid clearing of bilirubin and decreased enzyme levels but no difference between steroid-treated and untreated cases in resolution of histologic lesions [25] [26] [27] . With the discovery of HBsAg, there has been concern that the use of steroids or other immunosuppressive therapy in acute hepatitis might lead to the induction of the carrier state. Steroids are efficacious in chronic hepatitis [28] and in acute hepatitis with biopsy evidence of subacute hepatic necrosis [13] . Steroids have a suppressing effect on in vivo skin tests and in vitro assays of delayed hypersensitivity [29, 30] . In this report steroids appeared to prevent the in vitro detection of MIF. In cases in which MIF was initially found, subsequent treatment with steroids obliterated detectable MIF activity.
The inhibitory mechanism of steroids in this study was obscure. Claman et al. [31, 32] have reported that the effect of steroids on tuberculin reactions is on the nonimmune macrophage and not on the thymus-derived (T) lymphocyte, which retains its ability to transfer cellular immunity. However, other investigators [33] have demonstrated a quantitative decrease in lymphocytes, predominately in T-cells, in normal people given 60 mg of prednisone. In our patients, no skin tests for sustained generalized anergy were performed; clinically, this was an unlikely explanation for lack of MIF detection, since most patients recovered from hepatitis and few had recognized underlying immunosuppressive disorders. However, transient anergy to tuberculin during acute measles infection is a well known phenomenon. It is possible that a combination of the above mechanisms may account for the inability to detect MIF in steroid-treated patients.
Similarly, in pregnancy, delayed hypersensitivity to HB!<Ag may be obscured in vitro. Pregnancy is often considered to be the most common human immunological expression of tolerance to the graft-vs-host response. Steroid levels are generally increased in pregnancy. In this study, one pregnant patient continued to circulate HBsAg in her blood until a therapeutic abortion was performed. Antigenemia rapidly cleared after abortion, perhaps as a result of a change in her immune response.
Although it is of interest that steroids significantly influenced the in vitro test for MIF to HBsAg, the data do not indicate that steroids should be routinely used to treat acute HBIlAgpositive hepatitis. Further clinical studies are needed in this area.
The interpretation of these findings and the observations on MIF production with regard to the pathogenesis of hepatitis B must be approached with caution. Since it is generally accepted that HBsAg is closely related to the virus causing hepatitis B, the observations reported here for delayed hypersensitivity to Hls.Ag in vitro may provide an explanation of the spectrum of clinical disease. One can only speculate at this point, but it would appear that the host's immunological response may determine which type of Irwin et al. clinical disease develops. Whether the immune response of the host to HBsAg is related to the virulence of the viral strains, HBsAg subtypes, linkage with histocompatibility antigens, or route or dose of inoculum remains to be determined.
